Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study

What Was Tested

Researchers studied Insulin Detemir in this randomized controlled trial publication.

This post-hoc sub-analysis investigated whether age (<65 years vs ≥65 years) affects glycemic control or hypoglycemic risk in patients with type 2 diabetes mellitus (T2DM) treated with once-daily insulin detemir.

Who Took Part

The abstract describes 2812 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

This was a 26-week, randomized, open-label, phase IV trial involving 2812 patients at 1083 predominantly primary care sites throughout the United States, of which 541 were designated for investigator-led insulin titration.

Patients were stratified by age in the sites designated for the investigator-led titration of insulin detemir.

How the Study Was Run

The design is described as randomized and open-label.

Because people in this Insulin Detemir study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Insulin Detemir was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Safety measures included adverse events and change in hypoglycemic event rates from baseline to Week 26.

What Was Measured

The subject headings attached to it are Algorithms, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin Detemir.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Detemir in 2812 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Drugs & aging), a journal based in New Zealand.

More context: the Insulin Detemir compound page.